Manipulation of costimulatory signals to enhance antitumor T-cell responses.
about
Science gone translational: the OX40 agonist storyCharacterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOSAntibody Therapies in Cancer.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Mechanisms of ganglioside inhibition of APC function.Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells.The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.The new vaccines: building viruses that elicit antitumor immunity.Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Combining Vaccines with Conventional Therapies for Cancer.Enhancing efficacy of therapeutic vaccinations by combination with other modalities.Peptide-based vaccination for colorectal cancer.Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.Association between the CD28 IVS3 +17T>C (rs3116496) polymorphism and cancer susceptibility: a meta-analysis involving 8,843 subjects.Immunomodulatory therapy for melanoma: ipilimumab and beyondRapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP miceImmune surveillance against a solid tumor fails because of immunological ignorance.Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response.An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants.Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer.The role of CTLA-4 in the regulation and initiation of T-cell responses.Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-alpha and CD40 ligand expression on B lymphoma cells.CD86 gene variants and susceptibility to pancreatic cancer.Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro.Immune checkpoint inhibitors in cancer therapy.Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma.The association between CD28 gene rs3116496 polymorphism and breast cancer risk in Chinese women.Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.Cardiotoxicity of immune checkpoint inhibitors.The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
P2860
Q27022436-30BA7DDD-1ED2-4F84-AA4E-C3A5417BBFB1Q28139731-E547558B-D526-49F1-AB73-923E12A63EB3Q31104000-52B766E2-97D9-44F7-BBD0-AFAC73325966Q33732329-C53E7510-606E-47F0-BE3A-811028613DBDQ33769786-CF3821F2-D30D-4CBD-8552-EF09D283DEF7Q34169329-92D06C87-CD9E-40B1-800F-F33378EE6683Q35047632-1501A6F5-6AC7-488D-9513-917B007D5C61Q35946203-97A3AB5E-AFF0-40E0-AB08-0037B784383DQ36004284-1F0BCAF0-753C-4400-994E-CC467AD8CCDDQ36082331-7785AB34-6E9C-4922-A87E-93B56080DFA3Q36113943-EDCC6C50-6A6E-4447-9955-EFD2FE9B601DQ36161221-83BC4DEC-6FFF-43E1-B25E-0548A563F406Q36292335-5C10E2A2-96B4-4000-9518-34FA0568FCD1Q36404076-5916F823-FBFA-4D2A-8E90-021874AF744FQ36411497-62C86006-2645-4052-BDAF-24C08745498DQ36841621-600755A7-48BD-4A12-881A-7E638634CEA0Q36844160-ADE4D4B2-E404-4FC0-9A34-F633D344B7D6Q37178041-5D97C5B6-DD14-4565-93B2-8FF9C5867B23Q37809156-6BA2FC83-9F85-45B2-AB5C-734855F085BEQ38002896-616C53C6-9291-4F9A-93B9-C1892CAB2A3AQ38577834-8EB9154E-46C1-4697-BF9E-9ED5F62CB417Q38996832-DA072215-1F41-4DF5-9D9B-AB0F79E0CE8EQ40614567-DBBB1089-766E-407E-8C9A-121A531F4DB8Q40711676-5A54E8CC-EE87-4AC4-9761-9DD41C1EF383Q40849487-13F3BD4E-2F0D-4BA3-BFC1-4ECEE6567817Q40959666-36C0A5C6-A73E-4771-BEC5-434E10E3D2CFQ41095702-632DE1AB-F7BB-42FF-A3F5-F0AB9D247D8DQ41332079-2BD4D80B-E9B3-4D95-BE6B-9AF19058B0A4Q41901715-098B4128-96F7-4133-A223-EBD4F2CECE99Q43218579-FA37C509-5F43-485E-AC14-765587A52D04Q44052198-52717E1D-BCEC-4215-A067-F611F3C56981Q44672300-2CCBE8F6-DB51-4659-8447-3BD3387610A0Q45862575-BD41146D-F32C-426B-B975-00FED8779F4DQ45871487-51B189F6-1957-401C-9C61-A5831DCA52CEQ46276232-E4DA9549-5C0B-46B4-A56A-0CCB641C9D57Q47098289-0386785C-8482-449A-BA17-52DB83C84BD5Q48362318-32E7CA09-2536-4A5C-8618-B63DB7409B75Q55438414-4C8A0903-0E72-4E3C-AF53-E45C2801F0A4Q56900194-0E6BF877-9E6D-4150-9FF8-D48CE4D67BAB
P2860
Manipulation of costimulatory signals to enhance antitumor T-cell responses.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Manipulation of costimulatory signals to enhance antitumor T-cell responses.
@en
type
label
Manipulation of costimulatory signals to enhance antitumor T-cell responses.
@en
prefLabel
Manipulation of costimulatory signals to enhance antitumor T-cell responses.
@en
P1476
Manipulation of costimulatory signals to enhance antitumor T-cell responses
@en
P2093
A A Hurwitz
P304
P356
10.1016/0952-7915(95)80077-8
P577
1995-10-01T00:00:00Z